Champions Oncology (CSBR) Depreciation & Amortization (CF) (2013 - 2026)

Champions Oncology (CSBR) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $314000.0 in Q3 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 12.29% year-over-year to $314000.0 in Q3 2026; TTM through Jul 2026 was $1.3 million, a 13.94% decrease from a year earlier, with the FY2026 full-year figure at $1.4 million, down 16.04% from the prior year.
• Depreciation & Amortization (CF) for Q3 2026 stood at $314000.0, down from $321000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $583000.0 in Q2 2023 and bottomed at $314000.0 in Q3 2026.
• Historically, Depreciation & Amortization (CF) has averaged $442526.3 across 5 years, with a median of $445000.0 in 2023.
• The widest annual swing landed in 2022, when Depreciation & Amortization (CF) jumped 87.46%; it then decreased 21.61% in 2024.
• Year by year, Depreciation & Amortization (CF) stood at $560000.0 in 2022, then dropped by 13.57% to $484000.0 in 2023, then decreased by 17.56% to $399000.0 in 2024, then retreated by 10.53% to $357000.0 in 2025, then fell by 12.04% to $314000.0 in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $314000.0 in Q3 2026, $321000.0 in Q2 2026, and $341000.0 in Q1 2026.